TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00999531
Drug: GS-9411
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inhaled GS-9411 dissolved in sterile saline
Study: NCT03473574
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: standard chemotherapy
Study: NCT03473574
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard chemotherapy
Study: NCT00000421
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00526513
Drug: Insulin Glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: subcutaneous injection of insulin glulisine at meal, 1 to 3 injections a day based on the condition of the patient in addition to a basal SC insulin injection at bedtime
Study: NCT01976338
Drug: Ranibizumab 0.5 mg
Normalized name: ranibizumab 0.5 MG in 0.05 ML Injection
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravitreal injection of 0.05 ml
Study: NCT02595450
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.
Study: NCT00698243
Drug: OSI-027
Normalized name: OSI-027
DrugBank: OSI-027 (DB12387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01655914
Drug: Flumazenil
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01448486
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral raltegravir, 400 mg tablet, twice daily for one year.
Study: NCT01934556
Drug: Ranibizumab 0.3 mg intravitreal injection
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00777608
Drug: Donepezil 5 - 10 mg
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil 1 capsule (5 mg) orally, once daily for 14 days.~Donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84).
Study: NCT00777608
Drug: Donepezil 10 mg
Normalized name: donepezil 10 mg oral tablet
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil 2 capsules (total 10 mg) orally, once daily for 24 weeks, from day 85 (optional).
Study: NCT03148132
Drug: Bevacizumab Injection
Normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.5mg/0.02 mL
Study: NCT03148132
Drug: Ranibizumab Ophthalmic
Normalized name: ranibizumab ophthalmic
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.25mg/0.025 mL
Study: NCT00934830
Drug: Antibiotic (Amoxicillin)
Normalized name: Amoxicillin
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg, 3 times per day for 10 days
Study: NCT03247972
Drug: Evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sixty subjects will be treated with high dose statins for 8 weeks followed by 8 weeks of high dose statin + evolocumab (420mg/4 wk) therapy.
Study: NCT01383486
Drug: Advil
Normalized name: Advil
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Commercially available Advil; oral caplet upon incidence of pain
Study: NCT00655590
Drug: Levitra (Vardenafil, BAY38-9456)
Normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg daily dosing
Study: NCT00655590
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg daily dosing
Study: NCT01010932
Drug: Dotarem
Normalized name: Dotarem
DrugBank: Gadoteric acid (DB09132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive one injection of Dotarem 0.2ml/kg
Study: NCT02115347
Drug: Ertugliflozin 15 mg
Normalized name: ertugliflozin 15 MG
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet
Study: NCT03600467
Drug: SEVI-D (Seviteronel in combination with dexamthasone)
Normalized name: aminophenazone, combinations with psycholeptics
DrugBank: Aminophenazone (DB01424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of SEVI-D (Serivteronel and dexamethasone) in the treatment of androgen receptor positive solid tumours.~Serivteronel will be administered orally at 450 mg (3 tables) once daily. It will be given in combination with one oral tablet of 0.5 mg tablet of Dexamethosone. SEVI-D will be continuously administered daily while on the study.~Clinical and safety assessments are scheduled every 4 weeks during the study and then every 8 weeks after the end of the safety follow up period of the study.
Study: NCT02297763
Drug: quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient body weight \<50kg : quetiapine 12.5mg patient body weight \>=50kg : quetiapine 25mg~quetiapine 12.5mg (bwt \<50kg ) or 25mg (bwt\>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form.~The study medicine(quetiapine) was provided as liquid form (medicine was pulverized and melted in 10cc water).
Study: NCT01307215
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mLs of 0.5%
Study: NCT01307215
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30mLs of 0.33%
Study: NCT01986491
Drug: JNJ 39393406 30 mg solid X
Normalized name: JNJ-39393406
DrugBank: JNJ-39393406 (DB11867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).
Study: NCT01986491
Drug: JNJ 39393406 120 mg solid X
Normalized name: JNJ-39393406
DrugBank: JNJ-39393406 (DB11867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).
Study: NCT01307215
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mLs of 0.25%
Study: NCT01986491
Drug: JNJ 39393406 30 mg solution
Normalized name: JNJ-39393406
DrugBank: JNJ-39393406 (DB11867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ 39393406 30 mg/mL solution orally (by mouth).
Study: NCT01471886
Drug: Ketorolac Tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every 8 hours for 4 days.
Study: NCT00274027
Drug: tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02580279
Drug: EGCG
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03341156
Drug: Kcentra
Normalized name: Kcentra
DrugBank: Prothrombin (DB11311)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kcentra will be administered in 2 divided doses; Pre-bypass (5-10 units/kg based on body weight and preoperative INR and post-protamine based of the pre-bypass dose and the preoperative INR; daily maximum dose not to exceed 5000 IU (50 IU/kg)
Study: NCT03891784
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03829930
Drug: Entinostat
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entinostat is formulated for oral administration. A food effect is evident for entinostat; exposure is significantly reduced when entinostat is administered with a high fat meal. Accordingly, entinostat is to be administered on an empty stomach, at least 1 hour before and 2 hours after a meal. Entinostat tablets should not be split, crushed, or chewed. Consult the individual clinical protocols for specific dosing instructions.~Dose level 1: 3mg PO weekly. Dose level 2: 5mg PO weekly.
Study: NCT03829930
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose level 1: 160 mg PO daily. Dose level 2: 160 mg PO daily.
Study: NCT01188889
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib will be given continuously at a fixed daily dose of 400 mg once daily.
Study: NCT00834340
Drug: Glimepiride 4 mg Tablets
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 4 mg, single-dose fasting
Study: NCT03620591
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative administration of lidocaine
Study: NCT01258504
Drug: St. Johns Wort
Normalized name: St. johns wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19.~* Administration of SJW: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20
Study: NCT00705211
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe, 10-mg tablets,
Study: NCT00705211
Drug: Ezetimibe + other lipid-lowering medication(s)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe, 10-mg tablets, other lipid-lowering medication(s) as prescribed by attending physician
Study: NCT01531920
Drug: alcohol + perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part A: alcohol + perampanel
Study: NCT01531920
Drug: perampanel + alcohol
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part B: perampanel + alcohol
Study: NCT01066364
Drug: Colesevelam Hcl
Normalized name: colesevelam HCl
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3.75 gm/day (six 675 mg tablets)
Study: NCT03574090
Drug: Amoxicillin Clavulanate
Normalized name: amoxicillin / clavulanate
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.
Study: NCT03451773
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard (1,000 mg/m\^2) or reduced (600 mg/m\^2 for 4 doses) intravenous (IV) once a week for first 4 weeks. Then, once weekly for 3 weeks with one week rest. Gemcitabine will be discontinued after 6 months of therapy
Study: NCT00308152
Drug: Infusion of 1 litre of normal saline before colonoscopy
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehydration with normal saline
Study: NCT00235352
Drug: CX516 (Ampakine)
Normalized name: CX516
DrugBank: CX516 (DB06247)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00528788
Drug: doxercalciferol
Normalized name: Doxercalciferol
DrugBank: Doxercalciferol (DB06410)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02469753
Drug: NSAIDs
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuous daily
Study: NCT01617460
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Flexibly dose administered orally once daily
Study: NCT01140360
Drug: Gleevec
Normalized name: Gleevec
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with a BSA \> 1.8 m2 or 55 mg/m2 twice daily for patients with BSA \< 1.8 m2. For patients with a BSA \> 1.8 m2 the dose will increase by increments of 100 mg bid every two weeks as tolerated up to a maximum dose of 400 mg bid. For patients with a BSA \< 1.8 m2 the dose will increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum dose of 220 mg/m2 bid.Treatment will continue for 6 months with an option to continue for 24 months if the patient is deriving a clinical benefit.
Study: NCT01491919
Drug: Lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be randomized to Low, Medium, or High dose of Lisinopril
Study: NCT02469753
Drug: NSAIDs
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: on demand
Study: NCT04467424
Drug: ketamine, propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anesthesia with ketofol in pediatric surgery
Study: NCT04467424
Drug: ketamine, propofol, lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anesthesia with ketofol plus lidocaine in pediatric surgery
Study: NCT02951715
Drug: zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 months of treatment with zinc gluconate (Zinga 78 mg, 10 mg elemental zinc), two tablets twice per day (40 mg per day)
Study: NCT01566773
Drug: PT001 MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as two puffs BID for 14 days
Study: NCT01566773
Drug: Tiotropium Bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taken as 1 capsule containing 18 µg of tiotropium via the Handihaler DPI
Study: NCT00390546
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00390546
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00762892
Drug: Raltegravir and truvada
Normalized name: Truvada
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir 400 mg po bid, truvada 1 tab q daily
Study: NCT00762892
Drug: Atazanavir, Norvir and Truvada
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Atazanavir 300 mg po q daily, Norvir 100 mg po q daily and Truvada 1 tablet po q daily
Study: NCT00670319
Drug: Raloxifene HCL
Normalized name: raloxifene HCl
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene HCL 60 mg orally once daily
Study: NCT00670319
Drug: Raloxifene HCL
Normalized name: raloxifene HCl
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene HCL 120 mg orally once daily
Study: NCT04369937
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between programmed cell death protein 1 (PD-1) and its ligands, PD-L1 and PD-L2.
Study: NCT04369937
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT03265574
Drug: Enalapril
Normalized name: Enalapril
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril is an Angiotensin Converting Enzyme (ACE) inhibitor which supresses the reninangiotensin-aldosterone system resulting in increased plasma renin activity and decreased aldosterone secretion
Study: NCT02294786
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib was supplied as 250mg tablets that are oval, biconvex, and orange film-coated with one side plain and the opposite side debossed, or as 250mg tablets that are oval, biconvex, and yellow film-coated with one side plain and the opposite side debossed. Each tablet contained 405mg of Lapatinib ditosylate monohydrate, equivalent to 250mg Lapatinib free base
Study: NCT02294786
Drug: Octreotide
Normalized name: Octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide (Sandostatin LAR™) was supplied as sterile 5milliliter (mL) vials delivering 20mg Octreotide as the free peptide. When mixed with diluent (approximately 2mL or 2.5 mL) it becomes a suspension that is given as an intramuscular injection. Two 20mg intramuscular injections were given to deliver a total dose of 40mg. The Octreotide is uniformly distributed within the microspheres which are made of a biodegradable glucose star polymer, D,L-lactic and glycolic acids copolymer. Sterile mannitol was added to the microspheres to improve suspendability
Study: NCT00571064
Drug: Donepezil HCl
Normalized name: donepezil HCl
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 5 mg tablet per day (for the first 6 weeks) with a full glass of water. For the last 6 weeks, one 10mg tablet per day with a full glass of water.
Study: NCT00784420
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir 400 mg twice daily for 10 days
Study: NCT01773109
Drug: Etirinotecan pegol (NKTR-102)
Normalized name: Certolizumab Pegol
DrugBank: Etirinotecan pegol (DB14951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Eligible patients will receive etirinotecan pegol at a dose of 145 mg/m2 iv every 3 weeks. One cycle will be defined as 3 weeks. Treatment will be administered on an outpatient basis.
Study: NCT02812121
Drug: umbilical cord blood mesenchymal stem cells
Normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01033734
Drug: oseltamivir [Tamiflu]
DrugBank: Oseltamivir acid (DB02600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day course (10 doses), intravenous administration, may be switched to oral administration at the discretion of the investigator; up to 5 additional days of treatment possible.
Study: NCT02614586
Drug: TAK-058
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-058 oral solution.
Study: NCT02614586
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron capsule.
Study: NCT02614586
Drug: Ondansetron Placebo
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron placebo-matching, capsule.
Study: NCT00520936
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1910 milligrams per meter squared (mg/m\^2) (or 60 milligrams per kilogram \[mg/kg\] if patient \<12 months old), intravenous (IV), for 21 days x 17 cycles
Study: NCT03080298
Drug: BP101
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01996293
Drug: lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine will be observed in women who have already under the guidance of a physician decide to continue lamotrigine for the treatment of Bipolar Disorder
Study: NCT03025477
Drug: CC0 - Carboplatin (IV) - Paclitaxel (IV)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: (6 cycles)
Study: NCT03025477
Drug: CC0 - Cisplatin (IP) - Epirubicin (IV)
Normalized name: Cisplatin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (6 cycles)
Study: NCT03025477
Drug: CC>0 - Carboplatin (IV)- Paclitaxel (IV)
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * carboplatin (IV) - paclitaxel (IV) (3 cycles)~* Interval surgery~* Carboplatin (IV) - paclitaxel (IV) (3 cycles)
Study: NCT03025477
Drug: CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Cisplatin (IV) - Epirubicin (IV) (3 cycles)~* Interval surgery :~  * if CC0: Cisplatin (IP) - Epirubicin (IV) (3 cycles)~ * if CC\>0 Cisplatin (IV)- Epirubicin (IV) (3 cycles)
Study: NCT02197637
Drug: ORAL VINORELBINE
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally vinorelbine 60 mg/m2 D1, 8 and 15 Cycle of 28 days For a maximum of 12 cycles The dose of vinorelbine should be increased to 80 mg/m2 from the 2nd cycle If on D8 and D15, the administration conditions are not met, the administration is canceled and not delayed.
Study: NCT00867568
Drug: TPI 287
Normalized name: TPI-287
DrugBank: TPI-287 (DB17168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three patients will be enrolled to receive single agent TPI 287 IV administered on Days 1, 8 and 15 of the first and second 28-day cycle. The starting dose of 90 mg/m2 (Dose Level 1) is 75% of the established adult MTD for this schedule in adults, which is 125 mg/m2. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.
Study: NCT00003437
Drug: asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003437
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003437
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003437
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00920816
Drug: Axitinib (AG-013736)
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: axitinib will be given at a starting dose of 5 mg BID with continuous dosing
Study: NCT00920816
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sorafenib will be given at a dose of 400 mg BID continuous dosing
Study: NCT00003437
Drug: pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003437
Drug: thioguanine
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003437
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02936427
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: perineural infiltration of dexamethasone